Rubicon Research Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 2,54,141 shares,. Its Average Traded Price (ATP) is ₹1734.33, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 100 @ ₹1771.70.
Rubicon Research has an upper circuit limit of ₹2126.00 and a lower circuit limit of ₹1417.40. The total value traded stands at ₹44.08 CR, and the delivery percentage for the day is 45.38%.
The stock is currently traded with a market lot size of 1. Rubicon Research also offers a dividend yield of 0.08%.
Rubicon Research Share Price Chart
Rubicon Research Share Key Metrics
Volume
2.54 L
Market Cap
29327.29 CR
LTQ@LTP
100@1771.70
ATP
1734.33
Var Margin
100 %
Circuit Range
1417.4-2126
Delivery %
45.38 %
Value
44.08 CR
ASM/GSM
No
Market Lot
1
Rubicon Research Resistance and Support
Pivot 1734.33
Resistance
First Resistance
1815.26
Second Resistance
1858.83
Third Resistance
1939.76
Support
First Support
1690.76
Second Support
1609.83
Third Support
1566.26
Rubicon Research Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-05 | Quarterly Results |
| 2026-08-14 | Quarterly Results |
| 2026-05-29 | Audited Results & Final Dividend |
| 2026-02-03 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-08-07 | 2026-08-07 | View More |
Rubicon Research News
Rubicon Research Ltd - 544578 - Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5, 2026
Rubicon Research reported Q2 FY27 cons. revenue of ₹576.38 crores and net profit of ₹90.43 crores, up 68% YoY. During the quarter, its wholly-owned subsidiary AdvaGen Holdings Inc. acquired a manufacturing facility in New Jersey, USA from InvaTech Pharma Solutions for USD 2.9 million.
Nov 05 2026 16:03:18
Rubicon Research Ltd - 544578 - Outcome Of USFDA Inspection Of Rubicon Research Ltd, Manufacturing Facility In Ambernath, India.
Rubicon Research received a USFDA Form 483 with 5 observations following an inspection of its Ambernath facility from 21-29 Oct 2026. All observations are procedural in nature with no data integrity issues.
Oct 30 2026 00:23:22
Rubicon Research Ltd - 544578 - Board Meeting Intimation for Q 2 Ended September, 2026.
Rubicon Research board of directors will meet on 5 November 2026 to approve the financial results. The results are for the quarter and half-year ended 30 September 2026.
Oct 27 2026 15:38:23
Rubicon Research Management
| Name | Position |
|---|---|
| Parag Suganchand Sancheti | Executive Director & Chief Executive Officer |
| Pratibha Sudhir Pilgaonkar | Managing Director |
Rubicon Research Similar Stocks
Dr. Lal Pathlabs Ltd.
2016.50
0.00 (0.00%)
Piramal Pharma Ltd.
246.37
0.00 (0.00%)
Wockhardt Ltd.
2031.50
0.00 (0.00%)
Acutaas Chemicals Ltd.
3882.60
0.00 (0.00%)
Krishna Institute of Medical Sciences Ltd
721.65
0.00 (0.00%)
Neuland Laboratories Ltd.
20322.00
0.00 (0.00%)
Granules India Ltd.
799.20
0.00 (0.00%)
Alembic Pharmaceuticals Ltd.
1017.30
0.00 (0.00%)
Astrazeneca Pharma India Ltd.
6514.50
0.00 (0.00%)
Onesource Specialty Pharma Ltd.
1618.00
0.00 (0.00%)
Rubicon Research FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in RUBICON
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC